| Name | Title | Contact Details |
|---|
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Telstar is a Trevose, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biosplice is developing first-in-class, small-molecule therapeutics based on pioneering science of alternative pre-mRNA splicing.
Ansa Biotechnologies is developing a new way to make DNA that will be faster, cleaner, and more accurate than existing methods.
Cellartis AB is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.